Alzheimer's Disease/Cognition News

An artificial intelligence-based machine learning model that diagnosed cognitive impairment in Alzheimer’s disease extracted information more accurately than standard screening or human analysis, according to a poster presentation at CTAD.

Time-dependent worsening of cognition and function among a cohort of individuals with biomarker-proven Alzheimer’s disease or dementia was accurately detected by a composite neurocognitive measure.

A novel, eye-tracking metrics device aided in the detection of dementia risk in a small population of Colombian individuals with differing levels of education, according to a poster presented at CTAD.

Mounting evidence suggests that herpes simplex virus 1 may be associated with an increased risk for Alzheimer’s disease and dementia, according to a systematic review of published studies.

For clinicians who treat patients with Alzheimer’s disease, quantification of amyloid positron emission tomography was feasible and possessed a high degree of concordance with visual analysis, according to a presentation at CTAD.

Technology was found to be both easy to use and highly acceptable in a cohort of those with Alzheimer’s-related agitation and their caregivers, according to a poster presentation at CTAD.

A customized speech transcription model logged roughly 30% fewer errors compared with manual or automated methods and may be a more effective tool in assessing verbal Alzheimer’s disease-related impairment.

Individuals with mild cognitive impairment performed faster on functional skills assessments and logged fewer dropouts when undergoing concurrent burst cognitive training, according to a poster from CTAD.

Participation in memory-based digital cognitive testing and blood-based biomarker assays for Alzheimer’s-related pathology was linked to successful enrollment into clinical trials for disease-modifying treatment, according to research.

Compared with placebo, donanemab slowed disease progression and reduced amyloid presence at 76 weeks for carriers and noncarriers of the APOE ε4 allele in early symptomatic Alzheimer’s disease, according to data presented at CTAD.